Lumbar cerebrospinal fluid proteome in multiple sclerosis: Characterization by ultrafiltration, liquid chromatography, and mass spectrometry

被引:65
作者
Noben, Jean-Paul
Dumont, Debora
Kwasnikowska, Natalia
Verhaert, Peter
Somers, Veerle
Hupperts, Raymond
Stinissen, Piet
Robben, Johan
机构
[1] Hasselt Univ, Inst Biomed Res, B-3590 Diepenbeek, Belgium
[2] Hasselt Univ, Dept Math Phys Informat Theoret Comp Sci, Diepenbeek, Belgium
[3] Transnatl Univ Limburg, Sch Life Sci, Diepenbeek, Belgium
[4] Delft Univ Technol, Fac Sci Appl, Analyt Biotechnol Grp, Delft, Netherlands
[5] Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands
关键词
centrifugal ultrafiltration; cerebrospinal fluid; cystatin A; gas phase fractionation; liquid chromatography; mass spectrometry; multiple sclerosis; proteomics; validation;
D O I
10.1021/pr0504788
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Neurological diseases, including multiple sclerosis (M.S.), often provoke changes in the functioning of the endothelial and epithelial brain barriers and give rise to disease-associated alterations of the cerebrospinal fluid (CSF) proteome. In the present study, pooled and ultrafiltered CSF of M. S. and non-M.S. patients was digested with trypsin and analyzed by off-line strong cation-exchange chromatography (SCX) coupled to on-line reversed-phase LC-ESI-MS/MS. In an alternative approach, the trypsin-treated subproteomes were analyzed directly by LC-ESI-MS/MS and gas-phase fractionation in the mass spectrometer. Taken together, both proteomic approaches in combination with a three-step evaluation process including the search engines Sequest and Mascot, and the validation software Scaffold, resulted in the identification of 148 proteins. Sixty proteins were identified in CSF for the first time by mass spectrometry. For validation purposes, the concentration of cystatin A was determined in individual CSF and serum samples of M. S. and non-M. S. patients using ELISA.
引用
收藏
页码:1647 / 1657
页数:11
相关论文
共 95 条
[21]   Application of proteomics technologies in the investigation of the brain [J].
Fountoulakis, M .
MASS SPECTROMETRY REVIEWS, 2004, 23 (04) :231-258
[22]  
Georgiou HM, 2001, PROTEOMICS, V1, P1503, DOI 10.1002/1615-9861(200111)1:12<1503::AID-PROT1503>3.0.CO
[23]  
2-M
[24]   Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF [J].
Gretzer, MB ;
Chan, DW ;
van Rootselaar, CL ;
Rosenzweig, JM ;
Dalrymple, S ;
Mangold, LA ;
Partin, AW ;
Veltri, RW .
PROSTATE, 2004, 60 (04) :325-331
[25]   A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease [J].
Guillaume, E ;
Zimmermann, C ;
Burkhard, PR ;
Hochstrasser, DF ;
Sanchez, JC .
PROTEOMICS, 2003, 3 (08) :1495-1499
[26]   Proteomic analysis of multiple sclerosis cerebrospinal fluid [J].
Hammack, BN ;
Fung, KYC ;
Hunsucker, SW ;
Duncan, MW ;
Burgoon, MP ;
Owens, GP ;
Gilden, DH .
MULTIPLE SCLEROSIS, 2004, 10 (03) :245-260
[27]   Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients [J].
Hansson S.F. ;
Puchades M. ;
Blennow K. ;
Sjögren M. ;
Davidsson P. .
Proteome Science, 2 (1)
[28]  
HARRINGTON MG, 1985, CLIN CHEM, V31, P722
[29]   High-resolution peptide mapping of cerebrospinal fluid:: a novel concept for diagnosis and research in central nervous system diseases [J].
Heine, G ;
Zucht, HD ;
Schuhmann, MU ;
Bürger, K ;
Jürgens, M ;
Zumkeller, M ;
Schneekloth, CG ;
Hampel, H ;
Schulz-Knappe, P ;
Selle, H .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 782 (1-2) :353-361
[30]  
Henskens YMC, 1996, BIOL CHEM H-S, V377, P71